Evidence mapPaperPMID 41864949Full record

ArticleStem cell research & therapy2026

Targeting p75NTR activity alleviates the neurotoxic effect of high glucose on iPSC-derived dopaminergic neurons.

Konstantina Chanoumidou, Ioanna Zota, Maria Anna Papadopoulou, Chrystalla Konstantinou, Alexandros Tsimpolis, Electra Tsagliotis, Maria Tziortziou, Katerina Ntarntani, Anne Grünewald, Matthieu David Lavigne and 2 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Konstantina ChanoumidouDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece. konstantina_chanoumidou@imbb.forth.gr.
Ioanna ZotaDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece.
Maria Anna PapadopoulouDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece.
Chrystalla KonstantinouDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece.
Alexandros TsimpolisDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece.
Electra TsagliotisInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, 71003, Heraklion, Greece.
Maria TziortziouLuxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Katerina NtarntaniDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece.
Anne GrünewaldLuxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Matthieu David LavigneInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, 71003, Heraklion, Greece.
Achille GravanisDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece.
Ioannis CharalampopoulosDepartment of Pharmacology, Medical School, University of Crete, 71003, Heraklion, Greece. charalampn@uoc.gr.

Funding

EMBO Scientific Exchange Grant STF_11143European Union HORIZON No 101099145European Union - NextGenerationEU TAEDR-0535850Fonds National de la Recherche Luxembourg PRIDE21/16749720Luxemburg National Research Fund (FNR) FNR9631103
6 · The paper itself

Abstract

backgroundHyperglycemia, a hallmark of diabetes mellitus, is a metabolic condition that highly affects the nervous system. While evidence from epidemiological and animal studies links diabetes to dopaminergic dysfunction and an increased risk of Parkinson's disease, the underlying mechanisms remain unclear. Here, we examined the effects of high glucose on human iPSC-derived dopaminergic neurons and glial cells to better understand the pathogenic alterations that lead to neurotoxicity. Previous implication of neurotrophins in the neurological manifestations of diabetes prompted us to focus on the role of p75NTR neurotrophin receptor (p75NTR) in dopaminergic neurodegeneration under hyperglycemic conditions.

methodsiPSC-derived dopaminergic neurons, astrocytes and microglia were treated with high glucose (50mM, 100mM) for 48 h to simulate hyperglycemia. Cytotoxicity assays, RNA sequencing and DNA damage assessments were employed to investigate the pathological alterations induced by high glucose exposure in neurons. Pharmacological targeting of p75NTR activity allowed investigation of its involvement in glucose neurotoxicity. Glial-mediated neurotoxicity was evaluated using conditioned media and inflammatory marker analysis.

resultsHigh glucose treatment led to DNA damage, activation of JNK signaling and cell death in neurons. Importantly, we observed upregulation of p75NTR and its pro-apoptotic ligand pro-NGF, suggesting activation of the pro-NGF/p75NTR axis in high glucose-treated neurons. Inhibition of p75NTR activity rescued neuronal cell death, identifying p75NTR as a central mediator of glucose neurotoxicity. Furthermore, glucose overload sensitized neurons to 6-hydroxydopamine (6-OHDA), increasing their vulnerability to neurotoxic insults-an effect reversed by p75NTR blockade. Treatment with BNN27, a synthetic NGF mimetic, prevented neuronal loss through p75NTR and TrkA receptors, suggesting neurotrophin signaling as a potential therapeutic target for combating high glucose-induced neuronal damage. Finally, we demonstrated the contribution of glial cells to neurodegeneration since high glucose treatment of iPSC-derived astrocytes and microglia enhanced their inflammatory potential and triggered the release of neurotoxic factors, causing pro-apoptotic effects on neurons.

conclusionsOur findings show that high glucose impairs human dopaminergic neuron survival through activation of the pro-NGF/p75NTR axis and indirect glia-mediated mechanisms. Targeting p75NTR signaling may offer neuroprotective benefits in diabetes-related neurodegeneration, particularly for patients at risk of Parkinson's disease.

Indexed as

Dopaminergic NeuronsGlucoseInduced Pluripotent Stem CellsReceptors, Nerve Growth FactorAstrocytesDNA DamageHumansHyperglycemiaMicrogliaNerve Tissue ProteinsGlucoseNerve Tissue ProteinsNGFR protein, humanReceptors, Nerve Growth FactorDopaminergic neuronsGlucotoxicityiPSCNeurodegenerationNeuroinflammationNeurotrophinsp75NTR

Identifiers

PMID41864949
PMCPMC13126899

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.